Connect with us

Health

European Commission Grants Ocugen Orphan Medicinal Product Designation for Gene Therapy Product Candidate, OCU400, For the Treatment of Both Retinitis Pigmentosa and Leber Congenital Amaurosis – GlobeNewswire

MALVERN, Pa., Feb. 23, 2021 (GLOBE NEWSWIRE) — Ocugen, Inc., (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and…

Published

on

ADVERTISEMENT

MALVERN, Pa., Feb. 23, 2021 (GLOBE NEWSWIRE) — Ocugen, Inc., (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that on the recommendation of the European Medicines Agency (EMA), the European Commission has granted orphan medicinal product designation for OCU400 (AAV5-hNR2E3), for the treatment of both retinitis pigmentosa (RP) and Leber…

Click here to view the original article.

Continue Reading
Advertisement

You might also like ...

Article feature image
Nicklaus Children’s Hospital offers COVID-19 vaccines for teens, young adults – WPLG Local 10
Article feature image
DHHS commissioner: Approach to COVID-19 will change in coming months – WMUR Manchester
Article feature image
P.1 variant, thought to be more contagious than other COVID-19 variants, confirmed in Chicago – WGN TV Chicago